T. Rowe Price Associates
TRAW icon

T. Rowe Price Associates’s Traws Pharma TRAW Stock Holding History

T. Rowe Price Associates’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3
Closed -$3.85M – 2518
2013
Q3 		$3.85M Buy
+3
New +$4.29M ﹤0.01% 1464

Other funds holding TRAW

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
WC
Weatherbie Capital Boston, Massachusetts $797M AUM 23.31% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates's TRAW Position: Q4 2013 in Review

T. Rowe Price Associates sold out of Traws Pharma (TRAW) in Q4 2013, closing a stake of 3 shares — an estimated $3.85M sold.

T. Rowe Price Associates first reported a position in TRAW in Q3 2013 and held it in 1 quarter. The position peaked at $3.85M in Q3 2013. 17 funds tracked by Wall St. Rank hold TRAW as of Q4 2013.

  • T. Rowe Price Associates reported no remaining Traws Pharma position as of Q4 2013 after selling out during the quarter.
  • T. Rowe Price Associates sold 3 Traws Pharma shares in Q4 2013, an estimated $3.85M.
  • T. Rowe Price Associates first reported a position in Traws Pharma in Q3 2013 and held it in 1 quarter.
  • T. Rowe Price Associates's Traws Pharma position peaked at $3.85M in Q3 2013.
  • 17 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2013.

Based on T. Rowe Price Associates's 13F filing for Q4 2013, filed 14 Feb 2014.